Picture Kentro Design Corporate and Web Design Berlin 650x65px
Document › Details

4SC AG. (4/30/12). "Press Release: 4SC Receives Milestone Payment from Research Collaboration with SKK". Planegg-Martinsried.

Organisation Organisation 4SC Discovery GmbH
  Today BioNtech Small Molecules GmbH
  Group BioNTech (Group)
Products Product drug discovery services
  Product 2 small-molecule drug
Person Person Vitt, Daniel (Immunic 201701– CEO before 4SC 1997–201612 CSO + Co-Founder before Univ Würzburg)

4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that it has received a milestone payment from the Japanese pharmaceutical company Sanwa Kagaku Kenkyusho Co. Ltd., Nagoya (SKK) under a previously-concluded research collaboration.

The milestone payment will go to 4SC Discovery GmbH, a wholly-owned subsidiary of 4SC AG specialising in the early-stage biopharmaceutical research and discovery of new drug substances.

Under the research collaboration, 4SC had contributed its know-how in the field of medicinal chemistry together with its expertise in computerised (in silico) screening and modelling for the rapid discovery, selection and optimisation of new drug substances (hits and leads) to investigate new classes of substances for the potential therapy of metabolic diseases. In its pharmaceutical research and development work, SKK has now achieved decisive progress with an optimised chemical compound resulting from this collaboration, which triggered the contractually-agreed milestone payment.

Dr. Daniel Vitt, Chief Scientific Officer of 4SC AG and Managing Director of 4SC Discovery GmbH commented: 'We are very pleased to have received this milestone payment. This success further stresses our long-standing research expertise and the capabilities of our core technology for the discovery and optimisation of new pharmaceutical compounds, a technology that we have been marketing more actively since early 2012 with the newly-launched 4SC Discovery. Our special thanks are due to our partner SKK for the fruitful and pleasant collaboration. We intend to use this and, in the future, similar ventures to further strengthen the business of both 4SC Discovery and the entire 4SC Group.'

End of press release

About 4SC

The Group (4SC) managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with a high unmet medical need in various autoimmune and cancer indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. 4SC AG, as the Group parent company, is concentrating on the clinical development of the drugs and their commercialisation together with pharmaceutical partners. 4SC Discovery GmbH, the fully-owned subsidiary of 4SC AG, is focused on the research and discovery of new therapeutic compounds - a measure also intended to further enhance the clinical development pipeline of 4SC AG - as well as their early-stage commercialisation. In addition, 4SC Discovery enters into service and collaboration agreements with pharmaceutical and biotech partners in the field of drug discovery. 4SC was established in 1997 and had 96 employees at the end of 2011. 4SC AG has been listed on the Prime Standard at the Frankfurt Stock Exchange since December 2005.

About SKK

Sanwa Kagaku Kenkyusho Co., Ltd. (SKK) is a fully-integrated pharmaceutical company headquartered in Nagoya, Japan. Their business is concentrated in research and development, manufacture, and sales of ethical pharmaceuticals, diagnostics, medical foods, health care products and contract manufacturing of pharmaceuticals. SKK's targeted therapeutic areas are metabolic disorders, renal diseases and ophthalmic diseases. Further information is available at:

Legal Note

This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.

For more information please visit and or contact:

Jochen Orlowski, Corporate Communications & Investor Relations
jochen.orlowski(at), Tel.: +49 (0) 89 70 07 63 66

MC Services
Raimund Gabriel
raimund.gabriel(at) , Tel.: +49 (0) 89 21 02 28 30

Mareike Mohr
mareike.mohr(at), Tel.: +49 (0) 89 21 02 28 40

The Trout Group (USA)
Chad Rubin
Crubin(at), Tel.: +1 646 378 2947

Record changed: 2019-06-09


Picture [iito] – Putting Information into Context 650x65px

More documents for BioNTech (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top